Edison Investment Research - Target Healthcare REIT PLC (THRL) Target Healthcare REIT - Continuing positive returns in Q4

Report

Edison Investment Research

Martyn King

Target Healthcare REIT - Continuing positive returns in Q4

Targetâ€™s portfolio of high-quality purpose-built care homes continues to grow and perform well with RPI-driven rental growth, increased property valuations, continuing acquisitions of operational homes and progress with pre-let forward-funded developments. Due diligence on potential further acquisition opportunities continues, in aggregate sufficient to fully deploy remaining debt capital resources.

20/08/2019 7 EN

Underlying

Target Healthcare REIT PLC

Target Healthcare REIT is engaged in the investment into care homes properties in the United Kingdom. Investment Manager: Target Advisers LLP

See profile

JE00B95CGW71 Jersey

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Martyn King

Other Reports on these Companies

SmartInsider

Target Healthcare Reit Ltd: 1 director

A director at Target Healthcare Reit Ltd maiden bought 24,052 shares at 83p and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The...

Free Trial

March 29, 2024 March 29, 2024 1 EN

EQS Group AG

Edison Investment Research Limited: Target Healthcare REIT (THRL): Consistent positive returns with social impact

Edison Investment Research Limited Edison Investment Research Limited: Target Healthcare REIT (THRL): Consistent positive returns with social impact 10-May-2021 / 07:00 GMT/BST London, UK, 10 May 2021 Target Healthcare REIT (THRL): Consistent positive returns with social impact Target Healthcare REIT has delivered consistently positive returns since IPO in 2013 and this has continued through the pandemic. Q321 EPRA NAV increased 0.8% to 109.1p and including DPS paid the NAV total return was 2.4%. In this note we provide an overview of company strategy and future prospects as...

May 10, 2021 May 10, 2021 1 EN

Edison Investment Research

Target Healthcare REIT - Consistent positive returns with social impact

Target Healthcare REIT has delivered consistently positive returns since IPO in 2013 and this has continued through the pandemic. Q321 EPRA NAV increased 0.8% to 109.1p and including DPS paid the NAV total return was 2.4%. In this note we provide an overview of company strategy and future prospects as the operator sector emerges from the worst impacts of the pandemic, and as Target deploys its strong capital resources, boosted by the £60m (gross) March equity raise, in accretive portfolio growth.

May 7, 2021 May 7, 2021 1 EN

Mendus - Regulatory endorsement supports vididencel focus

Mendus’s lead asset, vididencel, is fast approaching the pivotal stages of development in acute myeloid leukaemia (AML), with recent endorsements from both the FDA and EMA (on the design of the planned registrational trial). Separately, Mendus has decided to cease further development for its second asset, ilixadencel, after the termination of its collaboration agreement with Institut Bergonié, sponsor of the REGOMUNE trial. We note that the termination was due to this basket study being prematurely halted, and not specifically related to ilixadencel. We view Mendus’s new streamlined approach t...

January 3, 2025 January 3, 2025 1 EN

Toby Thorrington

Toby Thorrington

Melrose Industries - Fundamentals remain positive

The aerospace sector outlook remains positive, with lengthy order books at the primes (Airbus and Boeing) and total passenger flying hours in 2024 on schedule to exceed post-pandemic levels, supporting a strong aftermarket. The former will assist margin recovery for Melrose Industries’ original equipment (OE) operations, while increased flying hours are already generating strong growth and margin in the aftermarket business. Hence, our adjustment to estimates for external factors, such as FX movements, should not detract investors from focusing on the underlying positive dynamics of the busine...

January 2, 2025 January 2, 2025 1 EN

Toby Thorrington

Toby Thorrington

Theon International - Record order book and upgrade to FY25

Theon International is a market leader in the defence optronics (night vision and thermal imaging) sector. Strong order intake, particularly in Q424, has enabled management to provide a positive outlook for FY25, including c 20% revenue growth. Adding in the mid-20% operating margins, we see the shares offering clear attractions on the current undemanding P/E rating of 11x in FY25e.

January 2, 2025 January 2, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Target Healthcare REIT - Continuing positive returns in Q4

Target Healthcare Reit Ltd: 1 director

Edison Investment Research Limited: Target Healthcare REIT (THRL): Consistent positive returns with social impact

Target Healthcare REIT - Consistent positive returns with social impact

Mendus - Regulatory endorsement supports vididencel focus

Melrose Industries - Fundamentals remain positive

Theon International - Record order book and upgrade to FY25

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe